Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III tria...

by David A. Wohl, Chloe Orkin, Manuela Doroana, José H. Pilotto, Somnuek Sungkanuparph, Patrick Yeni, Simon Vanveggel, Henri Deckx, Katia Boven
Published 2018

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

by Jean Michel Molina, Pedro Cahn, Beatriz Grinsztejn, Adriano Lazzarin, Anthony Mills, Michael Saag, Khuanchai Supparatpinyo, Sharon Walmsley, Herta Crauwels, Laurence T. Rimsky, Simon Vanveggel, Katia Boven
Published 2018

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO an...

by Calvin J. Cohen, Jean Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie, Beatriz Grinsztejn, Hao Wu, Margaret A. Johnson, Michael Saag, Khuanchai Supparatpinyo, Herta Crauwels, Eric Lefebvre, Laurence T. Rimsky, Simon Vanveggel, Peter Williams, Katia Boven
Published 2018